Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
Status:
Completed
Trial end date:
2014-10-10
Target enrollment:
Participant gender:
Summary
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as
rituximab, can block cancer growth in different ways. Some block the ability of cancer cells
to grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them. Giving bortezomib together with rituximab may kill more cancer cells.
This phase II trial is studying how well giving bortezomib together with rituximab works as
first-line therapy in treating patients with low-grade B-cell non-Hodgkin's lymphoma.